Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GDC-0587 Monotherapy and Combination With Giredestrant in ER+/HER2- Breast Cancer
NCT07214662Phase 1Terminated
- Sponsor
- Genentech
- Start
- Jan 2026
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of RGT-587 in breast cancer (3 arms), sponsored by Genentech. Primary endpoints: Percentage of Participants with Adverse Events up to 18 months and Percentage of Participants with Dose-limiting Toxicity at 28 days. Started Jan 2026; status: terminated.
02
Drugs
RGT-587
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07214662.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07214662.